Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05669820 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Antisecretory Factor Glioblastoma Phase 2

Study acronym: AFGB2
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Jan 1, 2025 to Dec 1, 2026
    • Study completion date: Jan 1, 2026 to Dec 1, 2027
    v5
  2. Start date changed from estimate of Aug 2023 to Jan 15, 2024v4
  3. Primary completion date: Jan 1, 2024 to Jan 1, 2025
    • Start date: May 2023 to Aug 2023
    • Study completion date: Jan 1, 2025 to Jan 1, 2026
    v3
  4. Start date: Jan 1, 2023 to May 2023v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Peter Siesjö
4 trials monitored
See all monitored trials
Glioma
1,251 trials monitored
See 88 trials at risk
Glioblastoma
710 trials monitored
See 52 trials at risk
This is a randomised, double blinded and multiple center , Phase 2 study in patients with newly diagnosed glioblastoma. Participants will receive an egg powder enriched for antisecretory factor (AF), Salovum, or a placebo egg powder daily from 2 days before concomitant radio-chemo therapy or chemotherapy until 14 days after finalisation plus during adjuvant chemotherapy.The primary aims of are overall survival at 6 and 12 months after diagnosis
Trial Details
NCT Number NCT05669820
Lead Sponsor Peter Siesjö
Collaborators: Lund University
Conditions
(from sponsor)		 Glioblastoma
Related terms Glioblastoma
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov